Pozelimab · Veopoz
Monoclonal antibody
Evidence outlook
Approved: adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also in development:Age-Related Macular Degeneration · Phase 3Generalized Myasthenia Gravis · Phase 3
Also approved (1)
- VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ACCESS-1 NCT05133531 · Paroxysmal Nocturnal Hemoglobinuria Registry: NCT05133531 | 3 | Percent change in lactate dehydrogenase (LDH) (From baseline to week 26); Transfusion avoidance (From post-baseline day 1 through week 26); Adequate control of hemolysis (From week 8 through week 26, inclusive) 2026-09-28 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 2 more trials
ACCESS-EXT NCT05744921 · Paroxysmal Nocturnal Hemoglobinuria Registry: NCT05744921 | 3 | Incidence of treatment-emergent serious adverse events (SAEs) (Up to week 108); Severity of treatment-emergent SAEs (Up to week 108); Incidence of treatment emergent adverse events of special interest (AESIs) (Up to week 108); Severity of treatment emergent AESIs (Up to week 108); Incidence of adverse events (AEs) leading to permanent treatment discontinuation (Up to week 108); Severity of adverse events (AEs) leading to permanent treatment discontinuation (Up to week 108); Percent change from baseline in lactate dehydrogenase (LDH) (Baseline to week 36) 2028-10-10 | In progress: results expected 10 Oct 2028 | not yet graded | link ↗ |
NCT07154745 NCT07154745 · Paroxysmal Nocturnal Hemoglobinuria Registry: NCT07154745 | 3 | Percent change in Lactate Dehydrogenase (LDH) during TP (From baseline to week 28) 2030-01-18 | In progress: results expected 18 Jan 2030 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Complement C5 drugs
Avacincaptad pegol, Eculizumab, Ravulizumab, Cemdisiran, Gefurulimab and 1 more. Compare all 7 Complement C5 drugs
6 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Generalized Myasthenia Gravis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pozelimab (Veopoz): this drug | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Partial signal | NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed | |
| Efgartigimod Alfa (Vyvgart) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Approved | Monoclonal antibody | CD19 | Reliable signal | NCT04524273: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4) | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Gefurulimab (Klygefa) | Phase 3 | Antibody-derived scaffold | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Phase 3 | Small molecule | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Aritinercept | Phase 1/2 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Veopoz (Pozelimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
May 2027 (1)
What to watch
2028 (3)
July 2028 (2)
October 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent